Search results
Showing 31 to 45 of 85 results for menopause
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
The medicine NICE recommends for most women who have been through the menopause is called anastrozole. However, this may not be suitable...
The medicine NICE recommends for most women who have been through the menopause is called anastrozole. However, this may not be suitable...
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.
View recommendations for HTG693Show all sections
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS90Show all sections
Sections for QS90
- Quality statements
- Quality statement 1: Diagnosing urinary tract infections in women under 65
- Quality statement 2: Diagnosing urinary tract infections in adults with catheters
- Quality statement 3: Antibiotic treatment for asymptomatic bacteriuria in men and non-pregnant women
- Quality statement 4: Duration of antibiotic treatment for urinary tract infection
- Quality statement 5: Referring adults with recurrent urinary tract infection
- Update information
- About this quality standard
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause is inadequate in quality and quantity. Therefore,...
Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.
View recommendations for HTG640Show all sections
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.